Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Safety of Gamifant® in Adult and Pediatric Patients With HLH/MAS in Still's Disease With Inadequate Response or Intolerance to Glucocorticoids, or With Recurrent MAS

NCT07909005 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07909005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Safety of Gamifant® in Adult and Pediatric Patients With HLH/MAS in Still's Disease With Inadequate Response or Intolerance to Glucocorticoids, or With Recurrent MAS
Lead sponsor
Swedish Orphan Biovitrum
Phase
Observational
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
December 31, 2030
Enrollment
70 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

hemophagocytic lymphohistiocytosis (hlh), macrophage activation syndrome (mas), still disease

Arms

As registered; 1 arm.

  • HLH/MAS in Still's disease treated with Gamifant Local Lab Tests, Local laboratory testing

    Patients aged ≤80 years at index Gamifant administration who have received at least 1 dose of Gamifant 0-7 days prior to ICF date or is prescribed to initiate Gamifant for the treatment of HLH/MAS in Still's disease

Primary endpoints

Registered primary outcome measures; 4 primary.

  • Outcome Measure: Incidence rate of treatment-emergent mycobacterium tuberculosis Timeframe: up to 12 months

    Description: Occurrence of treatment-emergent mycobacterium tuberculosis and non-tuberculosis mycobacterium. A TEAE is defined as any AE that occurs from the administration of the index dose of Gamifant until the initial 12 months of follow-up, regardless of relationship to Gamifant.

    Unit of Measure: Number of events per 100-patient year

  • Outcome Measure: Incidence rate of treatment-emergent non-tuberculosis mycobacterium infections Timeframe: up to 12 months

    Description: Occurrence of treatment-emergent mycobacterium tuberculosis and non-tuberculosis mycobacterium. A TEAE is defined as any AE that occurs from the administration of the index dose of Gamifant until the initial 12 months of follow-up, regardless of relationship to Gamifant.

    Unit of Measure: Unit of Measure: Number of events per 100-patient year

  • Outcome Measure: Incidence rate of treatment-emergent CMV reactivation and/or infection Timeframe: up to 12 months

    Description: Occurrence of treatment-emergent CMV disease including reactivation and/or infection. A TEAE is defined as any AE that occurs from the administration of the index dose of Gamifant until the initial 12 months of follow-up, regardless of relationship to Gamifant.

    Unit of Measure: Number of events per 100-patient year

  • Outcome Measure: Incidence rate of serious treatment-emergent infections Timeframe: up to 12 months

    Description: Occurrence of serious treatment-emergent infections (including CMV reactivation and/or infection, mycobacterium tuberculosis, and non tuberculosis mycobacterial infections). A TEAE is defined as any AE that occurs from the administration of the index dose of Gamifant until the initial 12 months of follow-up, regardless of relationship to Gamifant.

    Unit of Measure: Number of events per 100-patient year

Lead sponsor's other trials

Swedish Orphan Biovitrum, most recent start first.

Similar trials

Same condition (Macrophage Activation Syndrome) and phase, most recent start first.